51061-67-7

Usage

Uses

Used in Pharmaceutical Industry:
(4-PYRIDIN-2-YL-PHENYL)-ACETIC ACID is used as a building block for the synthesis of various pharmaceuticals due to its versatile chemical structure and potential pharmacological properties. It contributes to the development of new drugs with improved therapeutic effects and reduced side effects.
Used as a Non-Steroidal Anti-Inflammatory Drug (NSAID):
In the medical field, (4-PYRIDIN-2-YL-PHENYL)-ACETIC ACID is used as a non-steroidal anti-inflammatory drug, helping to reduce inflammation, pain, and fever. Its ability to inhibit cyclooxygenase (COX) enzymes plays a crucial role in its anti-inflammatory and analgesic effects.
Used as a Cyclooxygenase (COX) Inhibitor:
(4-PYRIDIN-2-YL-PHENYL)-ACETIC ACID functions as a cyclooxygenase (COX) inhibitor, which is essential in the treatment of various inflammatory conditions. By inhibiting COX enzymes, it reduces the production of prostaglandins, thereby alleviating inflammation and pain.
Used in Organic Synthesis:
In the field of organic chemistry, (4-PYRIDIN-2-YL-PHENYL)-ACETIC ACID serves as a reagent in various organic synthesis processes. Its unique structure allows for the creation of a wide range of organic compounds, further expanding its applications in research and development.
Used in Medicinal Chemistry Research:
(4-PYRIDIN-2-YL-PHENYL)-ACETIC ACID is of interest to researchers in medicinal chemistry due to its potential as a lead compound in the discovery of new drugs. Its pharmacological properties and chemical versatility make it a valuable tool in the design and synthesis of novel therapeutic agents.

Upstream product

• 109-09-1 2-chloropyridine 
• 52199-25-4 (4-Pyridin-2-yl-phenyl)-acetic acid ethyl ester 
• 14062-25-0 Ethyl 4-bromophenylacetate 
• 859169-20-3 1-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-acetic acid ethyl ester 
• 52199-24-3 2-[(4-bromomethyl)phenyl]pyridine 
• 4467-06-5 2-(4-methylphenyl)pyridine 
• 51061-63-3 (4-pyridin-2-yl-phenyl)-acetonitrile 

Downstream Products

• 485842-31-7 N-(5-(N-cyclopropylsulfamoyl)-4-methylthiazol-2-yl)-N-methyl-2-(4-(pyridin-2-yl)phenyl)acetamide 
• 139277-62-6 (4-Pyridin-2-yl-phenyl)-acetic acid hydrazide 

Relevant academic research and scientific papers

N-[5-(AMINOSULFONYL)-4-METHYL-1,3-THIAZOL-2-YL]-N-METHYL-2-[4-(2-PYRIDINYL)PHENYL]ACETAMIDE MESYLATE MONOHYDRATE

The present invention relates to an improved and shortened synthesis of N-[5- (aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acet-amide and the mesylate monohydrate salt thereof by using boronic acid derivatives or borolane r

N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate

The present invention relates to an improved and shortened synthesis of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide and the mesylate monohydrate salt thereof by using boronic acid derivatives or borolane rea

Compositions and methods of treating cell proliferation disorders

The invention relates to compounds and methods for treating cell proliferation disorders.

Thiazolyl amide derivatives

The present invention relates to novel compounds, to a process for their preparation and to their use as medicaments, in particular as antiviral medicaments.

Aromatic hydrazides as specific inhibitors of bovine serum amine oxidase

New hydrazides were synthesized in search for specific inhibitors of bovine serum amine oxidase: a series of benzoic and phenylacetic acid hydrazides containing the 1H-imidazol-1-yl or the 1H-imidazol-1-ylmethyl group as (o,m,p)-substituent in the phenyl ring; an analogous series of p-substituted phenylhydrazides with 5 or 6-membered heterocyclic ring as substituent, and a series of similar phenylpropionic hydrazides. The longer and more flexible phenylacetic hydrazides, and to a somewhat lesser extent the phenylpropionic ones, were better specific inhibitors of bovine serum amine oxidase than the benzoic hydrazides, which were also bound by the enzyme with high affinity, but at a slow rate. Derivatives with p- and m-substituents were more reactive than the o-substituted ones. The chemical nature of the substituent was less important than its position in the phenyl ring and the presence of methylene spacers. These data point to the presence of a hydrophobic site at short distance from the protein carbonyl cofactor, so that simultaneous interaction of the 2 ends of the inhibitor molecule can occur at the 2 sites. The presence of the hydrophobic site was confirmed by the capability of some molecule deprived of the hydrazidic group to act as mild inhibitors. All hydrazides were less reactive by 2-3 orders of magnitude towards pig kidney diamine oxidase and FAD-dependent monoamine oxidase from rat brain mitochondria, while the other compounds showed similar inhibition power against all proteins. The specificity for the bovine enzyme seems therefore to be related to the concerted action of the 2 moieties of the inhibitor molecule.